IMS 2022 | Can CAR-T therapy be used in conjunction with or instead of autologous transplantation in myeloma?
Krina Patel, MD, Msc, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the safety and efficacy of high-dose melphalan, discussing the possibility of CAR-T therapy being used in conjunction with or in place of autologous transplantation in the treatment of patients with multiple myeloma. Whilst melphalan is highly effective and accessible, it causes significant toxicity. If CAR-T therapy is proven to be as effective or more effective than transplant whilst preserving the patient’s quality of life (QoL), it could potentially replace transplantation or be used as a consolidation strategy following transplant. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
